Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning
| Autor: | Matthew Seftel, Ryan Del Bel, Wei Xu, Dennis Dong Hwan Kim, Naheed Alam, Jieun Uhm, Hans A. Messner, Nada Hamad, Jeffrey H. Lipton, John Kuruvilla, Vikas Gupta |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Allogeneic transplantation Transplantation Conditioning Survival Cyclophosphamide Adolescent Antineoplastic Agents Antibodies Monoclonal Humanized Graft-versus-host disease Young Adult immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans Aplastic anemia Alemtuzumab Transplantation Hematopoietic cell business.industry Hematopoietic Stem Cell Transplantation Anemia Aplastic Hematology Middle Aged medicine.disease Survival Analysis Surgery Fludarabine surgical procedures operative Treatment Outcome Female business medicine.drug |
| Zdroj: | Biology of Blood and Marrow Transplantation. 20(11):1722-1728 |
| ISSN: | 1083-8791 |
| DOI: | 10.1016/j.bbmt.2014.06.033 |
| Popis: | Graft-versus-host disease (GVHD) has no therapeutic benefit after hematopoietic cell transplantation (HCT) for patients with acquired aplastic anemia (AA), and its prevention is highly desirable. We designed a conditioning regimen using an intermediate dose of alemtuzumab (50 to 60 mg) and describe our institutional experience of 41 patients who underwent HCT for AA. The median age at HCT was 37 years (range, 17 to 59). The conditioning regimen was high-dose cyclophosphamide (n = 9) or fludarabine based (n = 32). Additional GVHD prophylaxis was with cyclosporine. With a median follow-up of 3.6 years, overall survival at 3 years was 85%. Survival in patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect